Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephropathy (PROTECT): 2-Year Results From a Randomised Active-Controlled Phase 3 Trial
Pivotal Results of the Phase 3 PROTECT Trial of Sparsentan vs Irbesartan in Patients With Immunoglobulin A Nephropathy
FILSPARI (sparsentan) – 2-Year Results from the Phase 3 DUPLEX Study Published in the NEJM
Sparsentan receptor occupancy modeling, clinical actions, and safety
Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial
Long-Term Efficacy and Safety of Sparsentan in Young Patients With FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)
Sparsetan Reduces Proteinuria in Patients with Immunoglobulin A Nephropathy (IgAN): Interim Results of the PROTECT Study
Preliminary Findings From the Phase 2 EPPIK Study of Sparsentan in Pediatric Patients With Selected Proteinuric Glomerular Diseases
Sparsentan receptor occupancy modeling, clinical actions, and safety
Sparsentan as First-Line Treatment of Incident Patients with IgA Nephropathy: Preliminary Findings from the SPARTAN Trial
Long-Term Efficacy and Safety of Sparsentan in Young Patients With FSGS: 240-Week Analysis of the DUET Open-Label Extension (OLE)
Sparsentan Publications 2023
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study